Manufacturer of Controlled Substances; Notice of Registration; Apertus Pharmaceuticals, 69134 [2013-27487]

Download as PDF 69134 Federal Register / Vol. 78, No. 222 / Monday, November 18, 2013 / Notices DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE DEPARTMENT OF LABOR Drug Enforcement Administration Drug Enforcement Administration Office of the Secretary Manufacturer of Controlled Substances; Notice of Registration: AMPAC Fine Chemicals, LLC. Manufacturer of Controlled Substances; Notice of Registration; Apertus Pharmaceuticals By Notice dated July 23, 2013, and published in the Federal Register on July 31, 2013, 78 FR 46372, AMPAC Fine Chemicals, LLC., Highway 50 and Hazel Avenue, Building 05001, Rancho Cordova, California 95670, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the following basic classes of controlled substances: By Notice dated July 23, 2013, and published in the Federal Register on July 31, 2013, 78 FR 46372, Apertus Pharmaceuticals, 331 Consort Drive, St Louis, Missouri 63011, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Agency Information Collection Activities; Submission for OMB Review; Comment Request; Current Population Survey—Displaced Worker, Job Tenure, and Occupational Mobility Supplement Drug Schedule Drug mstockstill on DSK4VPTVN1PROD with NOTICES Methylphenidate (1724) ................ Thebaine (9333) ........................... Poppy Straw Concentrate (9670) Tapentadol (9780) ........................ II II II II Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ The company is a contract manufacturer. In reference to Poppy Straw Concentrate the company will manufacture Thebaine intermediates to sell to its customers for further manufacture. No other activity for this drug code is authorized for registration. No comments or objections have been received. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007). DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of AMPAC Fine Chemicals, LLC., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated AMPAC Fine Chemicals, LLC., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 4, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Schedule The company plans to manufacture small quantities of the listed controlled substances to make reference standards for distribution to their customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Apertus Pharmaceuticals to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Apertus Pharmaceuticals to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 5, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–27487 Filed 11–15–13; 8:45 am] BILLING CODE 4410–09–P Jkt 232001 The Department of Labor (DOL) is submitting the Bureau of Labor Statistics (BLS) sponsored information collection request (ICR) titled, ‘‘Current Population Survey—Displaced Worker, Job Tenure, and Occupational Mobility Supplement,’’ to the Office of Management and Budget (OMB) for review and approval for reinstatement, without change, in accordance with the Paperwork Reduction Act of 1995 (PRA), 44 U.S.C. 3501 et seq. DATES: Submit comments on or before December 18, 2013. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained free of charge from the RegInfo.gov Web site at http:// www.reginfo.gov/public/do/ PRAViewICR?ref_nbr=201308-1220-001 (this link will only become active on the day following publication of this notice) or by contacting Michel Smyth by telephone at 202–693–4129 (this is not a toll-free number) or sending an email to DOL_PRA_PUBLIC@dol.gov. Submit comments about this request by mail or courier to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for DOL–BLS, Office of Management and Budget, Room 10235, 725 17th Street NW., Washington, DC 20503; by Fax: 202– 395–6881 (this is not a toll-free number); or by email: OIRA_ submission@omb.eop.gov. Commenters are encouraged, but not required, to send a courtesy copy of any comments by mail or courier to the U.S. Department of Labor-OASAM, Office of the Chief Information Officer, Attn: Information Policy and Assessment Program, Room N1301, 200 Constitution Avenue NW., Washington, DC 20210; or by email: DOL_PRA_PUBLIC@dol.gov. FOR FURTHER INFORMATION: Contact Michel Smyth by telephone at 202–693– 4129 (this is not a toll-free number) or by email at DOL_PRA_PUBLIC@dol.gov. SUMMARY: This ICR seeks to reinstate a previously approved SUPPLEMENTARY INFORMATION: BILLING CODE 4410–09–P 17:33 Nov 15, 2013 Notice. Authority: 44 U.S.C. 3507(a)(1)(D). [FR Doc. 2013–27484 Filed 11–15–13; 8:45 am] VerDate Mar<15>2010 II II II II ACTION: PO 00000 Frm 00095 Fmt 4703 Sfmt 4703 E:\FR\FM\18NON1.SGM 18NON1

Agencies

[Federal Register Volume 78, Number 222 (Monday, November 18, 2013)]
[Notices]
[Page 69134]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27487]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Apertus Pharmaceuticals

    By Notice dated July 23, 2013, and published in the Federal 
Register on July 31, 2013, 78 FR 46372, Apertus Pharmaceuticals, 331 
Consort Drive, St Louis, Missouri 63011, made application by renewal to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances to make reference standards for distribution to 
their customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a), and determined that the registration 
of Apertus Pharmaceuticals to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time.
    DEA has investigated Apertus Pharmaceuticals to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 
1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic classes of controlled substances listed.

    Dated: November 5, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-27487 Filed 11-15-13; 8:45 am]
BILLING CODE 4410-09-P